James Dennewill
Fortuna: 3 M $ al 31/08/2026
Fortuna: 3 M $ al 31/08/2026
James Dennewill is the Chief Operating Officer at SpyGlass Pharma, Inc. since 2021, with employment at the company starting in 2019.
Formerly, Mr. Dennewill was the Chief Operating Officer at Cianna Medical, Inc. Education includes an undergraduate degree from The California State University and an MBA from Yale School of Management.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
SPYGLASS PHARMA, INC. 0,29 % | 05/02/2026 | 96.022 ( 0,29 % ) | 3 M $ | 31/08/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| SPYGLASS PHARMA, INC. | Director de Operaciones | 01/10/2021 |
| Empresas | Cargo | Fin |
|---|---|---|
Cianna Medical, Inc.
Cianna Medical, Inc. Medical SpecialtiesHealth Technology Manufactures and designs medical products for treatment of early-stage breast cancer in women | Director de Operaciones | - |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 4 |
|---|---|
The California State University
The California State University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Cianna Medical, Inc.
Cianna Medical, Inc. Medical SpecialtiesHealth Technology Manufactures and designs medical products for treatment of early-stage breast cancer in women | Health Technology |
Yale School of Management
Yale School of Management Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
SpyGlass Pharma Inc
SpyGlass Pharma Inc BiotechnologyHealth Technology Operates as a biopharmaceutical company that develops IOL-mounted drug delivery platform for glaucoma patients | Health Technology |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.